Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 377 results
A minimalist illustration of a DNA strand and laboratory flask in flat design.

Jun 29, 2026

Nvidia (NASDAQ:NVDA) AI Push Faces Legal Test

Nvidia is making significant strides in the life sciences AI sector with its BioNeMo Agent Toolkit, but faces legal challenges that could impact its expansion.Nvidia's BioNeMo platform is gaining traction among life sciences and biotech firms, facilitating AI-driven workflows for drug discovery and laboratory automation. Its adoption by companies like Tecan and Biolevate indicates a shift from merely providing hardware to offering integrated software solutions that enhance operational efficiency
A glass vial of a drug compound on a laboratory bench with shelves of reagents in the background.

Jun 29, 2026

Edison Scientific Partners With Biotech Innovators to Pioneer AI-Driven Drug Discovery

A strategic partnership between Edison Scientific and Population Health Partners aims to revolutionize drug discovery through AI, significantly reducing development timelines and costs.In a groundbreaking alliance announced in June 2026, Edison Scientific, known for its advanced AI platforms, has teamed up with Population Health Partners to transform the drug discovery process. This collaboration will integrate Edison’s AI technology into the pharmaceutical pipeline managed by the innovative tea
A minimalist illustration of a vaccine vial and syringe on a dark background.

Jun 29, 2026

Likang Life Sciences Develops Personalized Cancer Vaccine with AI Technology - News and Statistics

Likang Life Sciences is pioneering the development of an AI-assisted personalized cancer vaccine, marking a significant advancement in China's healthcare landscape.The company has initiated the construction of what is touted as China's first production line dedicated to AI-assisted personalized tumor vaccines. This initiative aims to address a pressing health crisis, as cancer is the second leading cause of death in the country, potentially benefiting millions of patients annually. Likang Life S
A test tube with a colorful chemical compound in a lab setting

Jun 28, 2026

Insilico, SK Launch Up-to-$2.5B Neuroimmune AI Drug Collaboration

Insilico Medicine has entered a significant partnership with SK Biopharmaceuticals to develop AI-driven drug candidates targeting neuroimmune disorders, with the potential for financial returns reaching $2.5 billion.This collaboration will leverage Insilico's Pharma.AI platform, which specializes in target validation and molecule optimization. Insilico will focus on discovering and optimizing drug candidates based on targets identified by SK, which will handle late-stage development and commerci
A minimalist illustration of a pill in a dark setting.

Jun 27, 2026

AI Drug Discovery Reaches Clinical Proof at BIO 2026: China Beat the BIOSECURE Act to Science

The BIO International Convention in San Diego recently highlighted significant advancements in AI drug discovery, marking a pivotal moment for the biopharma industry. Notably, generative AI has transitioned from theoretical discussions to producing tangible clinical results, demonstrating its potential to revolutionize drug development.At BIO 2026, the conversation shifted from skepticism about AI's capabilities to a focus on what is currently effective in drug design and the urgency of rapid de
Minimalist illustration of a T-cell and drug compound in a biotech context.

Jun 25, 2026

Israeli-founded AI biotech Immunai launches drug-discovery collaboration with Boehringer Ingelheim

Immunai, an Israeli-founded AI biotech firm, has initiated a collaboration with Boehringer Ingelheim, focusing on drug discovery for T-cell targets in immuno-oncology and autoimmune diseases. This partnership, valued at up to $15 million and extending through 2027, aims to leverage Immunai’s advanced AI platform to analyze extensive patient data for potential therapeutic insights.The collaboration seeks to integrate research on cancer and autoimmune diseases, which are often studied in isolation
A test tube with a colorful chemical compound in a dimly lit lab

Jun 25, 2026

[BIO USA 2026] NVIDIA pushes agentic AI beyond coding and into drug discovery

NVIDIA is advancing its efforts in life sciences through the introduction of agentic AI, which aims to automate complex scientific workflows and enhance drug discovery processes.At the BIO USA 2026 event in San Diego, NVIDIA's Vice President of Healthcare, Kimberly Powell, discussed how AI has evolved from merely assisting researchers with data retrieval to performing tasks autonomously. This shift towards agentic AI signifies a move from generating information to executing multi-step scientific
Close-up of healthy hair follicles on a scalp in a clinical setting

Jun 24, 2026

Eli Lilly dives into hair loss treatments with investment in AI startup Absci

Eli Lilly is taking a strategic step into the hair loss treatment market by investing in the AI-driven startup Absci, which focuses on developing innovative medications for hair growth and possibly endometriosis.Absci recently secured $100 million in funding, with Eli Lilly contributing $40 million as part of the investment round. This move aligns with Lilly's broader strategy to diversify its portfolio beyond its successful weight loss drugs, Wegovy and Mounjaro, into other aesthetic and therap
Minimalist representation of an antibody and small molecule in a dark palette

Jun 24, 2026

The biotech bi-weekly: partnerships facilitating antibody discovery and AI drug development

The past two weeks have seen a surge in partnerships aimed at enhancing drug discovery, particularly in the realm of antibody development and small-molecule therapeutics.Notably, ChemDiv has made strides with its drug discovery platform focused on the central nervous system, facilitating the design of small molecules capable of penetrating the brain. This advancement supports both preclinical and clinical progress for its collaborators, illustrating the platform's potential in addressing neurolo
A laboratory vial with a drug compound in a dimly lit lab setting.

Jun 24, 2026

AI Drug Discovery Boosts Life Sciences Stock

The integration of artificial intelligence (AI) is significantly transforming the life sciences sector, particularly in drug discovery and development.AI technologies are enhancing the efficiency of research within pharmaceutical and biotechnology firms by leveraging advanced data analytics and predictive modeling. This evolution is particularly beneficial for companies with proprietary datasets, as AI tools enable them to extract greater value from existing resources. Notably, AI accelerates dr
A test tube with a bubbling chemical solution on a laboratory bench

Jun 24, 2026

Lilly Expands AI Drug Discovery Push With ‘App Store’ Model For Biotech Scientists

Eli Lilly is leveraging profits from its successful weight-loss and diabetes treatments to enhance its artificial intelligence initiatives, introducing a data-sharing platform for biotech researchers, likened to an "App Store" for scientists by CEO David Ricks. This move is part of a strategic diversification ahead of impending patent expirations for its key drugs in the 2030s.Lilly is heavily investing in AI infrastructure and collaborations to streamline drug discovery. The newly launched Lill
A minimalist illustration of a neuron and molecule in a dark palette.

Jun 24, 2026

Insilico Medicine, SK Biopharmaceuticals Sign Up to $2.5B AI Drug Discovery Pact for Neuroimmune Disorders

Insilico Medicine and SK Biopharmaceuticals have entered a significant collaboration worth up to $2.5 billion aimed at advancing AI-driven drug discovery for neuroimmune disorders.The partnership, announced at the BIO 2026 International Convention, will leverage Insilico's Pharma.AI platform to identify drug targets, optimize molecules, and enhance preclinical drug discovery specifically for conditions affecting the central nervous system (CNS). This initiative addresses critical unmet medical n